Ashwin Ragupathi

610 total citations
15 papers, 451 citations indexed

About

Ashwin Ragupathi is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy. According to data from OpenAlex, Ashwin Ragupathi has authored 15 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology and Allergy. Recurrent topics in Ashwin Ragupathi's work include Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Ashwin Ragupathi is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Ashwin Ragupathi collaborates with scholars based in United States. Ashwin Ragupathi's co-authors include Jason S. Lewis, Patrícia M. R. Pereira, Komal Mandleywala, Lukas M. Carter, Yelena Y. Janjigian, R. Brian Dyer, Dong Zhang, Manrose Singh, Brian M. Zeglis and Wolfgang Scholz and has published in prestigious journals such as Nature Communications, Chemical Communications and Clinical Cancer Research.

In The Last Decade

Ashwin Ragupathi

15 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashwin Ragupathi United States 10 204 184 173 53 45 15 451
Jacob Pourat United States 8 205 1.0× 163 0.9× 173 1.0× 35 0.7× 38 0.8× 9 388
Beate Müller‐Tiemann Germany 9 213 1.0× 305 1.7× 224 1.3× 84 1.6× 27 0.6× 12 548
Karolin Pohle Germany 11 298 1.5× 129 0.7× 176 1.0× 65 1.2× 12 0.3× 12 484
Thomas Sroka United States 10 147 0.7× 283 1.5× 101 0.6× 79 1.5× 24 0.5× 18 500
Daniel M. Freed United States 9 114 0.6× 334 1.8× 182 1.1× 71 1.3× 59 1.3× 19 581
Philipp Große-Gehling Germany 6 68 0.3× 175 1.0× 262 1.5× 53 1.0× 31 0.7× 6 412
Michela Aurilio Italy 15 178 0.9× 219 1.2× 195 1.1× 64 1.2× 10 0.2× 23 560
Zhengming Yan United States 12 67 0.3× 294 1.6× 211 1.2× 66 1.2× 28 0.6× 15 569
Micah John Luderer United States 12 136 0.7× 222 1.2× 160 0.9× 16 0.3× 31 0.7× 15 592
Jascha‐N. Rybak Switzerland 6 209 1.0× 276 1.5× 143 0.8× 20 0.4× 94 2.1× 7 550

Countries citing papers authored by Ashwin Ragupathi

Since Specialization
Citations

This map shows the geographic impact of Ashwin Ragupathi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwin Ragupathi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwin Ragupathi more than expected).

Fields of papers citing papers by Ashwin Ragupathi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwin Ragupathi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwin Ragupathi. The network helps show where Ashwin Ragupathi may publish in the future.

Co-authorship network of co-authors of Ashwin Ragupathi

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwin Ragupathi. A scholar is included among the top collaborators of Ashwin Ragupathi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwin Ragupathi. Ashwin Ragupathi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Singh, Manrose, et al.. (2024). A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination. Gynecologic Oncology Reports. 54. 101417–101417. 1 indexed citations
2.
Young, Melody W., Edwin Dickinson, Johnathan R. Yarbro, et al.. (2023). Three toes and three modes: Dynamics of terrestrial, suspensory, and vertical locomotion in brown‐throated three‐toed sloths (Bradypodidae, Xenarthra). Journal of Experimental Zoology Part A Ecological and Integrative Physiology. 339(4). 383–397. 5 indexed citations
3.
Young, Melody W., Johnathan R. Yarbro, Ashwin Ragupathi, et al.. (2023). Dynamics of horizontal walking and vertical climbing in the Australian green tree frog (Ranoidea caerulea). Journal of Experimental Biology. 226(7). 7 indexed citations
4.
Ragupathi, Ashwin, et al.. (2023). Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Frontiers in Cell and Developmental Biology. 11. 1133472–1133472. 60 indexed citations
5.
Pereira, Patrícia M. R., Komal Mandleywala, Sébastien Monette, et al.. (2022). Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nature Communications. 13(1). 2526–2526. 27 indexed citations
6.
Sharma, Sai Kiran, Pierre Adumeau, Outi Keinänen, et al.. (2021). Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry. 32(7). 1255–1262. 12 indexed citations
7.
Pereira, Patrícia M. R., Komal Mandleywala, Ashwin Ragupathi, & Jason S. Lewis. (2020). Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors. Clinical Cancer Research. 26(23). 6215–6229. 27 indexed citations
8.
Sharma, Sai Kiran, Thapi D. Rao, Kimberly J. Edwards, et al.. (2020). Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. Nuclear Medicine and Biology. 86-87. 9–19. 5 indexed citations
9.
Li, Qun, et al.. (2020). Site-Specific Tryptophan Labels Reveal Local Microsecond–Millisecond Motions of Dihydrofolate Reductase. Molecules. 25(17). 3819–3819. 1 indexed citations
10.
Pereira, Patrícia M. R., Komal Mandleywala, Ashwin Ragupathi, et al.. (2019). Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of Nuclear Medicine. 60(11). 1569–1578. 24 indexed citations
11.
Pereira, Patrícia M. R., et al.. (2019). HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. Molecular Pharmaceutics. 17(1). 327–337. 20 indexed citations
12.
Poty, Sophie, Lukas M. Carter, Komal Mandleywala, et al.. (2018). Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 25(2). 868–880. 72 indexed citations
13.
Poty, Sophie, Rosemery Membreno, Ashwin Ragupathi, et al.. (2018). The inverse electron-demand Diels–Alder reaction as a new methodology for the synthesis of225Ac-labelled radioimmunoconjugates. Chemical Communications. 54(21). 2599–2602. 39 indexed citations
14.
Pereira, Patrícia M. R., Sai Kiran Sharma, Lukas M. Carter, et al.. (2018). Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature Communications. 9(1). 5137–5137. 102 indexed citations
15.
Ragupathi, Ashwin, et al.. (2018). Characterizing the Surface Coverage of Protein–Gold Nanoparticle Bioconjugates. Bioconjugate Chemistry. 29(8). 2691–2700. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026